Labetalol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Labetalol" in English language version.

refsWebsite

Global rank English rank

19nih.gov

4^th place

14doi.org

2^nd place

4web.archive.org

1^st place

3books.google.com

3^rd place

3semanticscholar.org

11^th place

8^th place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

1fda.gov

447^th place

338^th place

1drugbank.com

low place

1hospira.com

low place

1parpharm.com

low place

1chemspider.com

8,573^rd place

low place

1hmdb.ca

low place

1pharmaxchange.info

low place

7,837^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 463. ISBN 9783527607495.
Narender R, Aggarawal G, Rohilla JK, eds. (1 January 2009). Elsevier Comprehensive Guide to Postgraduate Medical Entrance Examinations (PGMEE). Vol. 2. Elsevier India. pp. 449–. ISBN 978-81-312-1620-0.
Ganten D, Mulrow PJ (6 December 2012). Pharmacology of Antihypertensive Therapeutics. Springer Science & Business Media. pp. 147–. ISBN 978-3-642-74209-5.

chemspider.com

"C19H24N2O3". ChemSpider. 21 July 2022. Retrieved 1 August 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Labetalol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

MacCarthy EP, Bloomfield SS (1983). "Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects". Pharmacotherapy. 3 (4): 193–219. doi:10.1002/j.1875-9114.1983.tb03252.x. PMID 6310529.
Arulkumaran N, Lightstone L (December 2013). "Severe pre-eclampsia and hypertensive crises". Best Practice & Research. Clinical Obstetrics & Gynaecology. 27 (6): 877–884. doi:10.1016/j.bpobgyn.2013.07.003. PMID 23962474.
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ (May 2015). "Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review". Drug Alcohol Depend. 150: 1–13. doi:10.1016/j.drugalcdep.2015.01.040. PMID 25724076.
Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. (May 2017). "β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon". J Cardiovasc Pharmacol Ther. 22 (3): 239–249. doi:10.1177/1074248416681644. PMID 28399647.
Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM (February 2021). "Neuropsychiatric Consequences of Lipophilic Beta-Blockers". Medicina (Kaunas). 57 (2): 155. doi:10.3390/medicina57020155. PMC 7914867. PMID 33572109.
Richards DA, Tuckman J, Prichard BN (October 1976). "Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol". British Journal of Clinical Pharmacology. 3 (5): 849–855. doi:10.1111/j.1365-2125.1976.tb00637.x. PMC 1428931. PMID 9968.
MacCarthy EP, Bloomfield SS (August 1983). "Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects". Pharmacotherapy. 3 (4): 193–219. doi:10.1002/j.1875-9114.1983.tb03252.x. PMID 6310529. S2CID 20410587.
Louis WJ, McNeil JJ, Drummer OH (January 1984). "Pharmacology of combined alpha-beta-blockade. I". Drugs. 28 (Suppl 2): 16–34. doi:10.2165/00003495-198400282-00003. PMID 6151889. S2CID 46974416.
Lund-Johansen P (1 January 1988). "Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol". Journal of Cardiovascular Pharmacology. 11 (Suppl 2): S12 – S17. doi:10.1097/00005344-198800000-00004. PMID 2464093.
Lund-Johansen P (1 January 1984). "Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol". Drugs. 28 (Suppl 2): 35–50. doi:10.2165/00003495-198400282-00004. PMID 6151890. S2CID 46986875.
Donnelly R, Macphee GJ (August 1991). "Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol". Clin Pharmacokinet. 21 (2): 95–109. doi:10.2165/00003088-199121020-00002. PMID 1884570.
Peacock WF, Hilleman DE, Levy PD, Rhoney DH, Varon J (July 2012). "A systematic review of nicardipine vs labetalol for the management of hypertensive crises". Am J Emerg Med. 30 (6): 981–993. doi:10.1016/j.ajem.2011.06.040. PMID 21908132.
Woods PB, Robinson ML (March 1981). "An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents". J Pharm Pharmacol. 33 (3): 172–173. doi:10.1111/j.2042-7158.1981.tb13743.x. PMID 6116760.
Riva E, Mennini T, Latini R (December 1991). "The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers". British Journal of Pharmacology. 104 (4): 823–828. doi:10.1111/j.1476-5381.1991.tb12513.x. PMC 1908821. PMID 1687367.

drugbank.com

go.drugbank.com

"Labetalol: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 August 1984. Retrieved 1 August 2024.

drugs.com

"Labetalol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
"Labetalol Use During Pregnancy". Drugs.com. Retrieved 11 March 2019.

fda.gov

accessdata.fda.gov

"Trandate" (PDF). Prometheus Laboratories Inc. November 2010. Retrieved 3 November 2015.

hmdb.ca

"Human Metabolome Database: Showing metabocard for Labetalol (HMDB0014736)". Human Metabolome Database. 6 September 2012. Retrieved 1 August 2024.

hospira.com

"Labetalol hydrochloride" (PDF). Hospira. May 2015. Archived from the original (PDF) on 4 March 2016. Retrieved 3 November 2015.

nih.gov

pubmed.ncbi.nlm.nih.gov

MacCarthy EP, Bloomfield SS (1983). "Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects". Pharmacotherapy. 3 (4): 193–219. doi:10.1002/j.1875-9114.1983.tb03252.x. PMID 6310529.
Arulkumaran N, Lightstone L (December 2013). "Severe pre-eclampsia and hypertensive crises". Best Practice & Research. Clinical Obstetrics & Gynaecology. 27 (6): 877–884. doi:10.1016/j.bpobgyn.2013.07.003. PMID 23962474.
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ (May 2015). "Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review". Drug Alcohol Depend. 150: 1–13. doi:10.1016/j.drugalcdep.2015.01.040. PMID 25724076.
Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. (May 2017). "β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon". J Cardiovasc Pharmacol Ther. 22 (3): 239–249. doi:10.1177/1074248416681644. PMID 28399647.
Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM (February 2021). "Neuropsychiatric Consequences of Lipophilic Beta-Blockers". Medicina (Kaunas). 57 (2): 155. doi:10.3390/medicina57020155. PMC 7914867. PMID 33572109.
Richards DA, Tuckman J, Prichard BN (October 1976). "Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol". British Journal of Clinical Pharmacology. 3 (5): 849–855. doi:10.1111/j.1365-2125.1976.tb00637.x. PMC 1428931. PMID 9968.
MacCarthy EP, Bloomfield SS (August 1983). "Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects". Pharmacotherapy. 3 (4): 193–219. doi:10.1002/j.1875-9114.1983.tb03252.x. PMID 6310529. S2CID 20410587.
Louis WJ, McNeil JJ, Drummer OH (January 1984). "Pharmacology of combined alpha-beta-blockade. I". Drugs. 28 (Suppl 2): 16–34. doi:10.2165/00003495-198400282-00003. PMID 6151889. S2CID 46974416.
Lund-Johansen P (1 January 1988). "Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol". Journal of Cardiovascular Pharmacology. 11 (Suppl 2): S12 – S17. doi:10.1097/00005344-198800000-00004. PMID 2464093.
Lund-Johansen P (1 January 1984). "Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol". Drugs. 28 (Suppl 2): 35–50. doi:10.2165/00003495-198400282-00004. PMID 6151890. S2CID 46986875.
Donnelly R, Macphee GJ (August 1991). "Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol". Clin Pharmacokinet. 21 (2): 95–109. doi:10.2165/00003088-199121020-00002. PMID 1884570.
Peacock WF, Hilleman DE, Levy PD, Rhoney DH, Varon J (July 2012). "A systematic review of nicardipine vs labetalol for the management of hypertensive crises". Am J Emerg Med. 30 (6): 981–993. doi:10.1016/j.ajem.2011.06.040. PMID 21908132.
Woods PB, Robinson ML (March 1981). "An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents". J Pharm Pharmacol. 33 (3): 172–173. doi:10.1111/j.2042-7158.1981.tb13743.x. PMID 6116760.
Riva E, Mennini T, Latini R (December 1991). "The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers". British Journal of Pharmacology. 104 (4): 823–828. doi:10.1111/j.1476-5381.1991.tb12513.x. PMC 1908821. PMID 1687367.

ncbi.nlm.nih.gov

Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM (February 2021). "Neuropsychiatric Consequences of Lipophilic Beta-Blockers". Medicina (Kaunas). 57 (2): 155. doi:10.3390/medicina57020155. PMC 7914867. PMID 33572109.
Richards DA, Tuckman J, Prichard BN (October 1976). "Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol". British Journal of Clinical Pharmacology. 3 (5): 849–855. doi:10.1111/j.1365-2125.1976.tb00637.x. PMC 1428931. PMID 9968.
Riva E, Mennini T, Latini R (December 1991). "The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers". British Journal of Pharmacology. 104 (4): 823–828. doi:10.1111/j.1476-5381.1991.tb12513.x. PMC 1908821. PMID 1687367.

pubchem.ncbi.nlm.nih.gov

"Labetalol". PubChem. Retrieved 1 August 2024.
"labetalol | C19H24N2O3". PubChem. U.S. National Library of Medicine. Retrieved 4 November 2015.

parpharm.com

"Labetalol [package insert]. Spring Valley, NY: Par Pharmaceutical; 2011" (PDF). Archived from the original (PDF) on 10 December 2015. Retrieved 3 November 2015.

pharmaxchange.info

Mehta A (2007). "Adrenergics and Cholinergic their Biosynthesis, Metabolism and Structure Activity Relationships". Medicinal Chemistry of the Peripheral Nervous System. PharmaXChange.info. Archived from the original on 4 November 2010. Retrieved 16 October 2010.

semanticscholar.org

api.semanticscholar.org

MacCarthy EP, Bloomfield SS (August 1983). "Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects". Pharmacotherapy. 3 (4): 193–219. doi:10.1002/j.1875-9114.1983.tb03252.x. PMID 6310529. S2CID 20410587.
Louis WJ, McNeil JJ, Drummer OH (January 1984). "Pharmacology of combined alpha-beta-blockade. I". Drugs. 28 (Suppl 2): 16–34. doi:10.2165/00003495-198400282-00003. PMID 6151889. S2CID 46974416.
Lund-Johansen P (1 January 1984). "Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol". Drugs. 28 (Suppl 2): 35–50. doi:10.2165/00003495-198400282-00004. PMID 6151890. S2CID 46986875.

web.archive.org

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Labetalol hydrochloride" (PDF). Hospira. May 2015. Archived from the original (PDF) on 4 March 2016. Retrieved 3 November 2015.
"Labetalol [package insert]. Spring Valley, NY: Par Pharmaceutical; 2011" (PDF). Archived from the original (PDF) on 10 December 2015. Retrieved 3 November 2015.
Mehta A (2007). "Adrenergics and Cholinergic their Biosynthesis, Metabolism and Structure Activity Relationships". Medicinal Chemistry of the Peripheral Nervous System. PharmaXChange.info. Archived from the original on 4 November 2010. Retrieved 16 October 2010.